Speakers

Sarah Tabrizi is Director of the UCL Huntington’s Disease Centre, Joint Head of Department Neurodegenerative Disease at the UCL Queen Square Institute of Neurology, a Principal Investigator at the UK Dementia Research Institute, and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery.  

She leads an internationally recognised basic bench science and translational research team focussed on finding disease modifying therapies for Huntington’s disease. She was PI on the first successful phase 1/2b trial of an antisense oligonucleotide and currently serves on several SABs advising industry and health partners on the development of potential gene targeting and nucleic acid therapies for HD. Sarah has published over 425 original peer-reviewed publications, and has led and run early phase numerous clinical trials for HD. In 2024, she was elected to the Fellowship of the Royal Society and to the US National Academy of Medicine for her research in HD. Sarah has received many prizes and awards for her work, including the 2022 MRC Millennium Medal and the 2025 British Neuroscience Association Outstanding Contribution to Neuroscience Award.